Emergent BioSolutions Gains FDA Approval for 6-Count and 24-Count NARCAN Multipacks
Emergent BioSolutions won FDA approval for 6- and 24-pack NARCAN Nasal Spray, enabling expanded high-volume naloxone distribution and building on over 85 million doses shipped since 2016. With a 0.42% weight in Invesco RAFI US 1500 Small-Mid ETF, this approval may modestly boost the fund’s healthcare exposure.
1. FDA Approval Details
Emergent BioSolutions received supplemental NDA clearance for new 6-count and 24-count NARCAN Nasal Spray multipacks, marking the first over-the-counter 4 mg naloxone product available in bundled configurations designed for high-volume emergency response.
2. Expanded Distribution Potential
The multipack approval supports enhanced distribution flexibility for public health partners and retail channels, building on over 85 million doses delivered across the U.S. and Canada since the product’s 2016 launch.
3. ETF Impact on PRFZ
Emergent BioSolutions represents approximately 0.42% of the Invesco RAFI US 1500 Small-Mid ETF; stronger product momentum and potential revenue gains could provide a modest positive contribution to the ETF’s healthcare segment.